GlassScriptPhysician profile
Sujay Madduri
NPI 1962738351
$392.10
in general payments reported to CMS, 2019-2025
13 companies · $44.01 in 2025
The $44.01 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $40.94 · 2021: $13.89 · 2022: $48.73 · 2023: $24.97 · 2025: $44.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $86.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.35 | 2019 | |
| Pfizer INC. | $34.62 | 2019-2020 | |
| Novo Nordisk INC | $26.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.52 | 2019-2020 | |
| Abbvie INC. | $24.97 | 2023 | |
| Tandem Diabetes Care, INC. | $24.50 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $21.08 | 2022 | |
| Ascendis Pharma Endocrinology INC | $19.51 | 2025 | Yorvipath |
| Medtronic, INC. | $15.32 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2019 | |
| Amgen INC. | $13.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujay Madduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.